Comvita hosed down shareholder speculation. Kind of.
Listed transport heavyweight boosts revenue and profit while noting highly uncertain outlook.
The ASX-listed bioscience company posted a strong second half and its guidance for 2026 is bullish.
Hiving off a minority stake in Highbrook Business Park seen as a more attractive option than an equity issue.
Trade software-as-a-service business reported annual loss of $3.5m in FY25.
The cervical cancer screening device company's board warned in November it might not survive without raising more cash.
The company completed a $1b capital raise earlier this year to pay down debt.
NZX-listed waste management company landed a $40m contract earlier this month.
Investment company seeks to balance its portfolio and cashflows.
The listed respiratory company says there will be a 50 basis point impact from US tariffs on hospital products sourced from New Zealand.